Literature DB >> 26661174

A novel mechanism of neuroprotection: Blood glutamate grabber.

José Castillo1, María Isabel Loza2, David Mirelman3, José Brea2, Miguel Blanco4, Tomás Sobrino4, Francisco Campos4.   

Abstract

Glutamate excitotoxicity is a primary contributor of ischemic neuronal death and other cellular components of the neurovascular unit. Several strategies have been developed against glutamate excitotoxicity, however none of them have not shown positive results in the clinical practice so far. Nowadays, the concept of blood/brain glutamate grabbing or scavenging is well recognized as a novel and attractive protective strategy to reduce the excitotoxic effect of excess extracellular glutamate that accumulates in the brain following an ischemic stroke. The main advantage of this novel therapeutic strategy is that it occurs in the blood circulation and therefore does not affect the normal brain neurophysiology, as it has been described for other drug treatments used against glutamate excitotoxicity. In this work we report all experimental data from the beginning of our studies, focused on stroke pathology, and we describe new findings about the potential application of this therapy. Future clinical trials will allow to know the real efficacy of this novel therapeutic strategy in stroke patients.
© The Author(s) 2015.

Entities:  

Keywords:  Blood–brain barrier; brain ischemia; experimental; glutamate; neuroprotection

Mesh:

Substances:

Year:  2015        PMID: 26661174      PMCID: PMC4759671          DOI: 10.1177/0271678X15606721

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  64 in total

1.  Pyruvate's blood glutamate scavenging activity contributes to the spectrum of its neuroprotective mechanisms in a rat model of stroke.

Authors:  Matthew Boyko; Alexander Zlotnik; Benjamin F Gruenbaum; Shaun E Gruenbaum; Sharon Ohayon; Ruslan Kuts; Israel Melamed; Adi Regev; Yoram Shapira; Vivian I Teichberg
Journal:  Eur J Neurosci       Date:  2011-09-21       Impact factor: 3.386

2.  High blood glutamate oxaloacetate transaminase levels are associated with good functional outcome in acute ischemic stroke.

Authors:  Francisco Campos; Tomás Sobrino; Pedro Ramos-Cabrer; Mar Castellanos; Miguel Blanco; Manuel Rodríguez-Yáñez; Joaquín Serena; Rogelio Leira; José Castillo
Journal:  J Cereb Blood Flow Metab       Date:  2011-01-26       Impact factor: 6.200

Review 3.  Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists.

Authors:  Keith W Muir
Journal:  Curr Opin Pharmacol       Date:  2005-12-15       Impact factor: 5.547

Review 4.  Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview.

Authors:  Stephen Grupke; Jason Hall; Michael Dobbs; Gregory J Bix; Justin F Fraser
Journal:  Clin Neurol Neurosurg       Date:  2014-12-03       Impact factor: 1.876

Review 5.  Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?

Authors:  Chrysanthy Ikonomidou; Lechoslaw Turski
Journal:  Lancet Neurol       Date:  2002-10       Impact factor: 44.182

6.  Plasma levels of glutamate during stroke is associated with development of post-stroke depression.

Authors:  Sai-Yu Cheng; Yan-Dong Zhao; Jie Li; Xiao-Yan Chen; Ruo-Dan Wang; Jun-Wei Zeng
Journal:  Psychoneuroendocrinology       Date:  2014-05-17       Impact factor: 4.905

7.  Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

Authors:  Werner Hacke; Geoffrey Donnan; Cesare Fieschi; Markku Kaste; Rüdiger von Kummer; Joseph P Broderick; Thomas Brott; Michael Frankel; James C Grotta; E Clarke Haley; Thomas Kwiatkowski; Steven R Levine; Chris Lewandowski; Mei Lu; Patrick Lyden; John R Marler; Suresh Patel; Barbara C Tilley; Gregory Albers; Erich Bluhmki; Manfred Wilhelm; Scott Hamilton
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

8.  Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis.

Authors:  Maarten G Lansberg; Erich Bluhmki; Vincent N Thijs
Journal:  Stroke       Date:  2009-05-28       Impact factor: 7.914

9.  High plasma glutamate levels are associated with poor functional outcome in acute ischemic stroke.

Authors:  Xiang-en Meng; Na Li; Da-Zhi Guo; Shu-Yi Pan; Hang Li; Chen Yang
Journal:  Cell Mol Neurobiol       Date:  2014-09-05       Impact factor: 5.046

Review 10.  Stroke epidemiology in Thailand.

Authors:  Nijasri C Suwanwela
Journal:  J Stroke       Date:  2014-01-31       Impact factor: 6.967

View more
  25 in total

1.  Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus.

Authors:  Dainan Zhang; Alexandra J Mably; Dominic M Walsh; Michael J Rowan
Journal:  Cereb Cortex       Date:  2017-07-01       Impact factor: 5.357

2.  Characterization of the L-glutamate clearance pathways across the blood-brain barrier and the effect of astrocytes in an in vitro blood-brain barrier model.

Authors:  Hans Cc Helms; Blanca I Aldana; Simon Groth; Morten M Jensen; Helle S Waagepetersen; Carsten U Nielsen; Birger Brodin
Journal:  J Cereb Blood Flow Metab       Date:  2017-02-01       Impact factor: 6.200

3.  Excess glutamate secreted from astrocytes drives upregulation of P-glycoprotein in endothelial cells in amyotrophic lateral sclerosis.

Authors:  Loqman A Mohamed; Shashirekha S Markandaiah; Silvia Bonanno; Piera Pasinelli; Davide Trotti
Journal:  Exp Neurol       Date:  2019-04-09       Impact factor: 5.330

4.  Phytoestrogen isoflavone intervention to engage the neuroprotective effect of glutamate oxaloacetate transaminase against stroke.

Authors:  Savita Khanna; Richard Stewart; Surya Gnyawali; Hallie Harris; Maria Balch; James Spieldenner; Chandan K Sen; Cameron Rink
Journal:  FASEB J       Date:  2017-06-27       Impact factor: 5.191

Review 5.  Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment.

Authors:  Nishit Pathak; Sunil Kumar Vimal; Ishi Tandon; Lokesh Agrawal; Cao Hongyi; Sanjib Bhattacharyya
Journal:  Metab Brain Dis       Date:  2021-11-01       Impact factor: 3.584

6.  Neuritin Promotes Bone Marrow-Derived Mesenchymal Stem Cell Migration to Treat Diabetic Peripheral Neuropathy.

Authors:  Zuo Zhang; Yuanzhi Liu; Jiyin Zhou
Journal:  Mol Neurobiol       Date:  2022-08-20       Impact factor: 5.682

Review 7.  Glutamate Efflux across the Blood-Brain Barrier: New Perspectives on the Relationship between Depression and the Glutamatergic System.

Authors:  Benjamin Fredrick Gruenbaum; Alexander Zlotnik; Amit Frenkel; Ilya Fleidervish; Matthew Boyko
Journal:  Metabolites       Date:  2022-05-20

Review 8.  EAAT2 as a Research Target in Bipolar Disorder and Unipolar Depression: A Systematic Review.

Authors:  Caren J Blacker; Vincent Millischer; Lauren M Webb; Ada M C Ho; Martin Schalling; Mark A Frye; Marin Veldic
Journal:  Mol Neuropsychiatry       Date:  2019-07-23

Review 9.  The Role of NLRP3 Inflammasome in Cerebrovascular Diseases Pathology and Possible Therapeutic Targets.

Authors:  Rongrong Bai; Yue Lang; Jie Shao; Yu Deng; Reyisha Refuhati; Li Cui
Journal:  ASN Neuro       Date:  2021 Jan-Dec       Impact factor: 4.146

Review 10.  New Approaches in Nanomedicine for Ischemic Stroke.

Authors:  Clara Correa-Paz; Andrés da Silva-Candal; Ester Polo; Jérôme Parcq; Denis Vivien; Dusica Maysinger; Beatriz Pelaz; Francisco Campos
Journal:  Pharmaceutics       Date:  2021-05-20       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.